These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 17069061)

  • 61. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients.
    Slevin JT; Fernandez HH; Zadikoff C; Hall C; Eaton S; Dubow J; Chatamra K; Benesh J
    J Parkinsons Dis; 2015; 5(1):165-74. PubMed ID: 25588353
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Levodopa/carbidopa/entacapone for the treatment of early Parkinson's disease: a meta-analysis.
    Liao X; Wu N; Liu D; Shuai B; Li S; Li K
    Neurol Sci; 2020 Aug; 41(8):2045-2054. PubMed ID: 32162166
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Levodopa/Carbidopa Enteral Suspension: A Review in Advanced Parkinson's Disease.
    Hoy SM
    Drugs; 2019 Oct; 79(15):1709-1718. PubMed ID: 31549300
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The nurse's role in clinical trials.
    Amyot D; Gray P; Demong C; Wilson W; Murphy D; Watson J; Duff J
    Can Nurse; 1996 Nov; 92(10):30-2. PubMed ID: 9095759
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [The effect of Stalevo-dosing on quality of life of Parkinsonian patients with wearing-off].
    Bokor M; Szentesi A
    Ideggyogy Sz; 2010 Jul; 63(7-8):247-51. PubMed ID: 20812452
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson's disease experiencing mild wearing-off: a randomised, double-blind trial.
    Tolosa E; Hernández B; Linazasoro G; López-Lozano JJ; Mir P; Marey J; Kulisevsky J
    J Neural Transm (Vienna); 2014 Apr; 121(4):357-66. PubMed ID: 24253234
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.
    Smith LA; Jackson MJ; Al-Barghouthy G; Rose S; Kuoppamaki M; Olanow W; Jenner P
    Mov Disord; 2005 Mar; 20(3):306-14. PubMed ID: 15490461
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Long-term effectiveness of levodopa-carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson's disease.
    Valldeoriola F; Grandas F; Santos-García D; Regidor I; Catalán MJ; Arbelo JM; Puente V; Mir P; Parra JC
    Neurodegener Dis Manag; 2016 Aug; 6(4):289-98. PubMed ID: 27440190
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Levodopa/carbidopa/entacapone (Stalevo).
    Hauser RA
    Neurology; 2004 Jan; 62(1 Suppl 1):S64-71. PubMed ID: 14718682
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease.
    Müller T; Erdmann C; Muhlack S; Bremen D; Przuntek H; Goetze O; Woitalla D
    J Neural Transm (Vienna); 2006 Oct; 113(10):1441-8. PubMed ID: 16604302
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.
    Müller T; Kolf K; Ander L; Woitalla D; Muhlack S
    Clin Neuropharmacol; 2008; 31(3):134-40. PubMed ID: 18520980
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
    Ferreira JJ; Rocha JF; Falcão A; Santos A; Pinto R; Nunes T; Soares-da-Silva P
    Eur J Neurol; 2015 May; 22(5):815-25, e56. PubMed ID: 25649051
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease.
    Ferreira JJ; Rascol O; Poewe W; Sampaio C; Rocha JF; Nunes T; Almeida L; Soares-da-Silva P;
    CNS Neurosci Ther; 2010 Dec; 16(6):337-47. PubMed ID: 20653695
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Drugs for treating Parkinson disease.
    Belavic J
    Nursing; 2012 Jul; 42(7):69. PubMed ID: 22739529
    [No Abstract]   [Full Text] [Related]  

  • 77. Parkinson's disease. Therapeutic strategies to improve patient function and quality of life.
    Danisi F
    Geriatrics; 2002 Mar; 57(3):46-50; quiz 52. PubMed ID: 11899548
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease.
    Meppelink AM; Nyman R; van Laar T; Drent M; Prins T; Leenders KL
    Mov Disord; 2011 Feb; 26(2):331-4. PubMed ID: 20960486
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Drug therapy of Parkinson's disease].
    Zhou XD
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):193-6. PubMed ID: 4075905
    [No Abstract]   [Full Text] [Related]  

  • 80. Sinemet CR in the treatment of patients with Parkinson's disease already on long-term treatment with levodopa.
    Aarli JA; Gilhus NE
    Neurology; 1989 Nov; 39(11 Suppl 2):82-5; discussion 95. PubMed ID: 2586767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.